Clinical Trials Logo

Bioavailability clinical trials

View clinical trials related to Bioavailability.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06345950 Completed - Safety Clinical Trials

Pharmacokinetics and Safety of a New Micellar Glutathione Formulation

Start date: June 21, 2022
Phase: N/A
Study type: Interventional

This study seeks to determine the short-term effects of daily oral supplementation with a new micellar Glutathione formulation (LipoMicel) on the oral absorption and safety of glutathione in healthy volunteers. The primary objective of this study is to evaluate and compare the pharmacokinetics of a novel micellar Glutathione (GSH) formulation with that of a standard formulation as well as a liposomal GSH formulation. The secondary objective is to evaluate the safety of a new micellar GSH formulation with higher bioavailability in human participants over a 30-day study period.

NCT ID: NCT06214338 Completed - Bioavailability Clinical Trials

Blood Bioavailability of Two Different Doses of a β-alanine Supplement (BIo-β)

Bio-ß
Start date: February 12, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to To study the blood bioavailability of a sustained-release β-alanine granulated supplement of two different doses (10 g and 20 g).

NCT ID: NCT06043739 Completed - Bioavailability Clinical Trials

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Start date: September 22, 2023
Phase: Phase 1
Study type: Interventional

Open label study to assess relative bioavailability of filgotinib oral mini-tablet versus oral tablet formulation and effect of food on the mini-tablet formulation.

NCT ID: NCT05967377 Completed - Pharmacokinetics Clinical Trials

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

Start date: November 16, 2018
Phase: Phase 1
Study type: Interventional

This is a single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study in healthy male subjects comparing a 200 mg Sorafenib (Nexavar®) reference tablet (Regimen A) to XS005 Sorafenib Capsule A, 2 x 50 mg (Regimen B) and XS005 Sorafenib Tablet A,100 mg (Regimen C) formulation. It is planned to enroll 15 subjects who will receive single oral doses of investigational medicinal product (IMP) across 3 treatment periods.

NCT ID: NCT05840848 Completed - Bioavailability Clinical Trials

Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males

Start date: November 21, 2017
Phase: N/A
Study type: Interventional

In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial. Healthy males (n=6) ingested, with breakfast, a single dose of 15 mg β-carotene in combination with either a placebo, 25 mg iron or 30 mg zinc capsule. Blood samples were collected at baseline and hourly for 10 hours. The triacylglycerol-rich fraction (TRF) was analysed for concentrations of β-carotene and plasma for β-carotene, retinol, triacylglycerols, LDL- and HDL-cholesterol.

NCT ID: NCT05835258 Completed - Bioavailability Clinical Trials

Oral Bioavailability of Two Melatonin Supplements

MELFENIL
Start date: May 30, 2023
Phase: N/A
Study type: Interventional

Results from several clinical studies show that orally administered melatonin has low bioavailability and a very short half-life. Phenyl capsaicin, a synthetic analogue of capsaicin, might increase its bioavailability by inhibiting the enzymes involved in its hepatic metabolism. Thus, the hypothesis of the present study is that the administration of melatonin supplement with phenyl capsaicin presents greater bioavailability than a melatonin supplement that does not contain phenyl capsaicin.

NCT ID: NCT05826899 Completed - Bioavailability Clinical Trials

A Stable Isotope Study to Evaluate the Bioavailability of an Oat Protein-based Iron Delivery System

Start date: April 3, 2023
Phase: N/A
Study type: Interventional

In the current study, the OAT fibril - Fe SA (Fe-oat 1) and OAT fibril - Fe NaOH (Fe-oat 2) will both be studied in vivo, alone are oat fibril powder add iron supplement is soluble in water and oat fibril powder add iron supplement is soluble in water in a food matrix (acai puree and honey) to assess their promise as Fe food fortificants. This first in human study to bioavailability assessment and adverse effect of the OAT fibril - Fe SA (Fe-oat 1), OAT fibril - Fe NaOH (Fe-oat 2) and in a food matrix to assess their promise as Fe food fortificants. This study will be conducted with the following objectives. 1. To conduct a stable Fe isotope study to evaluate the bioavailability of OAT-Fe formulated using two reducing agents (Fe-oat 1 and Fe-oat-2) and compared to FeSO4. 2. To compare the performance of Fe-oat 1 and 2 in a food matrix containing Fe inhibitors, (acai puree and honey) in comparison to FeSO4 in a similar meal matrix.

NCT ID: NCT05646368 Completed - Bioavailability Clinical Trials

Bioavailability of Select Nutrients From Two Formulations of a Multivitamin/Mineral Supplement

Start date: December 23, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to assess the relative bioavailability of select nutrients from two formulations of a multivitamin/mineral supplement in healthy adults.

NCT ID: NCT05640531 Completed - Bioavailability Clinical Trials

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Start date: December 1, 2011
Phase: Phase 1
Study type: Interventional

The present study is planned to assess the safety and pharmacokinetic profile in normal healthy subjects in US for WCK 771 with doses ranging from 600 mg to 1000 mg BID for 5 days. In the proposed Phase I MAD study, a subject will be administered 600mg, 800mg, and 1000mg WCK 771 BID for 5 days (Ten doses) or an identical placebo as intravenous infusion.

NCT ID: NCT05627518 Completed - Pharmacokinetics Clinical Trials

Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

BA
Start date: November 15, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, randomized, single dose, 3-way crossover study in healthy volunteers designed to evaluate the relative bioavailability of a new oral tablet formulation of linaprazan glurate in comparison to a previously studied oral tablet formulation under fasting conditions, and to assess the effect of a high fat, high calorie meal on the pharmacokinetics (PK) of linaprazan glurate and the active substance linaprazan after the administration of the new oral tablet formulation.